Scopolamine transmucosal - Anesta

Drug Profile

Scopolamine transmucosal - Anesta

Alternative Names: Oral transmucosal system - scopolamine; OTS - scopolamine; Scopolamine oral transmucosal system

Latest Information Update: 23 Aug 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anesta Corporation
  • Class Antiemetics; Antispasmodics; Hypnosedatives; Mydriatics; Tropanes
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Nausea and vomiting

Most Recent Events

  • 23 Aug 2006 Discontinued - Phase-I for Emesis in USA (Transmucosal)
  • 01 Nov 2000 Anesta has been acquired by Cephalon
  • 24 Jul 2000 Phase-I clinical trials for Emesis in USA (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top